Press Releases

Nov 04, 2013

Veracyte, Inc. Announces Closing of Initial Public Offering

Read More

Oct 30, 2013

Veracyte, Inc. Announces Pricing of Initial Public Offering

Read More

Oct 23, 2013

Long-Term, Multicenter Outcome Study Confirms Clinical Validity and Clinical Utility of Veracyte's Afirma Gene Expression Classifier

Read More

Oct 18, 2013

Veracyte Presents Preliminary Data Suggesting Potential for an RNA-Based Gene Expression Test to Detect the BRAF V600E Mutation in Thyroid Nodule Biopsy Samples

Read More

Sep 20, 2013

Veracyte, Inc. Files Registration Statement for Initial Public Offering

Read More

Jul 08, 2013

Veracyte Receives Aetna Coverage for Its Afirma® Gene Expression Classifier for Use in Thyroid Cancer Diagnosis

Read More

Jun 28, 2013

Veracyte Completes $28 Million Series C Financing Round With GE Ventures as a New Investor

Read More

Apr 17, 2013

Veracyte Announces That New Study Suggests The Number Of Patients At Risk For Unnecessary Thyroid Surgery Is Likely On The Rise

Read More

Apr 12, 2013

Veracyte Announces Appointment of Shelly D. Guyer as Chief Financial Officer

Read More

Mar 12, 2013

Veracyte Announces Results of Study Assessing Use of BRAF Mutation Testing With Its Afirma® Gene Expression Classifier

Read More